Out now in Innovations in Pharmaceutical Technology, Optibrium’s Global Head of Application Science and President of Optibrium Inc, Dr Tamsin Mansley discusses the past, present and future of AI in drug discovery. She shares her thoughts on how AI technologies are best serving the drug discovery industry, how any limitations in the field are being tackled by innovations in technology and where the future of new drug discovery technologies look to be headed.

Introduction

For drug discovery, there are three key areas of chemistry in which artificial intelligence (AI) technologies can be applied: generative chemistry, synthesis planning and compound property prediction. Together, these cover which potential drug candidates could be considered, how to synthesise them, and whether they will have the required balance of properties to successfully meet the project’s objectives.

1] Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 2004 Aug;3(8):711–6.

About the author

Tamsin Mansley

Global Head of Application Science and President Optibrium Inc.

Profile

Tamsin Mansley, PhD

More AI in drug discovery resources

Related content from across the site

Meet with us atACS Fall 2024

Join Daniel Barr to hear more about how deep learning imputation prioritises the most relevant data, accounts for uncertainty, and guides experiment selection to bring additional value to small molecule discovery.